Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

The quest for specific anti-inflammatory treatment

08.01.2009
Anti-inflammatory drugs affect the cells taking part in inflammatory processes, but also those that do not. This is why it is important to develop specific anti-inflammatory drugs which affect healthy cells. With this aim in mind, a team from the University of the Basque Country is working on analogues of the C1P molecule.

Today two types of anti-inflammatory pharmaceutical drugs are available: steroids and those known as NSAID (Non-steroidal anti-inflammatory drugs). This second type are the most used, have fewer side-effects but they have an effect over a wider spectrum, i.e. they are less specific. Thus, there are no specific anti-inflammatory drugs for each cell type.

The team led by Antonio Gómez-Muñoz, from the Department of Biochemistry and Molecular Biology at the Science and Technology Faculty of the University of the Basque Country (UPV/EHU), is investigating alternatives to current anti-inflammatory drugs, creating synthetic analogues of the C1P (ceramide-1-phosphate) molecule. This molecule was discovered in 1990 in a case of human leukaemia After synthesising it in the laboratory, it was observed that it was an important mytogenic agent (provoking cell growth and blocking the natural death of the cells). Moreover, it causes cell inflammation, i.e. when the cells detect the presence of this molecule, they secrete molecules that generate inflammation - prostaglandin and cytokine cells, for example.

But this process does not occur with all types of cells. Although apparently contradictory, in some cells this same molecule functions in an anti-inflammatory manner. With this in mind, the Basque research team, annulling the inflammatory capacity of the C1P molecule, was able to use it as an anti-inflammatory drug for certain cell types without affecting other cells.

Removing one of the capabilities

To this end, and in collaboration with a research team from the University of Barcelona, they developed synthetic molecules similar in structure to that of C1P. The team is being led by doctors Josefina Casas and Gemma Fabriás, from the Consejo Superior para la Investigación Científica (CSIC) and includes Doctor Antonio Delgado from the University of Barcelona. They are the pharmacists and organic chemists who provide the UPV/EHU team with the made-to-measure molecules.

50 analogues of C1P have been tested to date of which three have provided the desired results, i.e. an anti-inflammatory function without causing inflammation in other cells These analogues do not generate prostaglandin, as does C1P and, thereby, do not produce any inflammation.

The three analogues mentioned have been tested with smooth muscle cells, with macrophages and with cancerous lung cells. The best results were obtained with the second and third type of cell. These types have been chosen as having a strong response to pro-inflammatory molecules.

Inflammation and cancer

Inflammatory processes may have various causes, an infection, for example. Chronic inflammatory diseases also exist, such as ulcerous colitis or multiple sclerosis, where, due to a constant state of inflammation, the cells are destabilised, provoking neoplasic processes, i.e. they generate new tissue of a tumorous nature. And this constant inflammation has great influence on the cells. They are destabilised and may cause an uncontrolled growth of the cells, even blocking their programmed death.

There are very few teams today researching the anti-inflammatory abilities of the C1P molecule – one team in Virginia (USA), the pharmaceutical company Novartis (Austria) and specific research teams such as that of Antonio Gómez-Muñoz, the first to investigate them in 1995. At present, the research is being undertaken at the cell level and shortly they should begin investigating with tissues and organs.

Lucía Álvarez | alfa
Further information:
http://www.elhuyar.com
http://www.basqueresearch.com/berria_irakurri.asp?Berri_Kod=2012&hizk=I

More articles from Life Sciences:

nachricht A cell senses its own curves: New research from the MBL Whitman Center
29.04.2016 | Marine Biological Laboratory

nachricht A New Discovery in the Fight against Cancer: Tumor Cells Switch to a Different Mode
29.04.2016 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Winzige Mikroroboter, die Wasser reinigen können

Forscher des Max-Planck-Institutes Stuttgart haben winzige „Mikroroboter“ mit Eigenantrieb entwickelt, die Blei aus kontaminiertem Wasser entfernen oder organische Verschmutzungen abbauen können.

In Zusammenarbeit mit Kollegen in Barcelona und Singapur verwendete die Gruppe von Samuel Sánchez Graphenoxid zur Herstellung ihrer Motoren im Mikromaßstab. D

Im Focus: Tiny microbots that can clean up water

Researchers from the Max Planck Institute Stuttgart have developed self-propelled tiny ‘microbots’ that can remove lead or organic pollution from contaminated water.

Working with colleagues in Barcelona and Singapore, Samuel Sánchez’s group used graphene oxide to make their microscale motors, which are able to adsorb lead...

Im Focus: Bewegungen in der lebenden Zelle beobachten

Prinzipien der statistischen Thermodynamik: Forscher entwickeln neue Untersuchungsmethode

Ein Forscherteam aus Deutschland, den Niederlanden und den USA hat eine neue Methode entwickelt, mit der sich Bewegungsprozesse in lebenden Zellen nach ihrem...

Im Focus: Faszinierender Blick in den Zellkern

Veröffentlichungen in Nature Communications zur DNA-Replikation

Vor jeder Zellteilung muss die Erbsubstanz kopiert werden. Die Startpunkte der DNA-Verdoppelung in Zellen von Menschen und Mäusen haben Wissenschaftler um...

Im Focus: Dauerbetrieb der Tokamaks rückt näher

Aussichtsreiche Experimente in ASDEX Upgrade / Bedingungen für ITER und DEMO nahezu erfüllt

Die ihrer Natur nach in Pulsen arbeitenden Fusionsanlagen vom Typ Tokamak sind auf dem Weg zum Dauerbetrieb. Alexander Bock, Wissenschaftler im...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

VDE|DGBMT veranstaltet Tagung zur patientennahen mobilen Diagnostik POCT

28.04.2016 | Veranstaltungen

Norddeutsche Herztage: 300 Experten treffen sich in Kiel

28.04.2016 | Veranstaltungen

Landwirtschaft und Lebensmittel - Analytische Chemiker: Wächter über Umwelt und Gesundheit

28.04.2016 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

SmartF-IT passt Produktionsprozesse flexibel an

29.04.2016 | Informationstechnologie

Neue Entdeckung im Kampf gegen Krebs: Tumorzellen stellen Betrieb um

29.04.2016 | Biowissenschaften Chemie

Fettreiche Ernährung lässt Gehirn hungern

29.04.2016 | Biowissenschaften Chemie